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ABSTRACT: There are a number of epidemiological studies that suggest the association 
of cardiovascular diseases and uric acid but very few studies highlight the direct 
association of deranged lipid profile with uric acid levels. The present study was indented 
to find out if any association exists between hyperuricemia and dyslipidemia. Blood 
samples were collected from healthy controls (n=70) and patients with dyslipidemia (n=70) 
who were not receiving any treatment for dyslipidemia. These samples were processed for 
estimating lipid profile and uric acid levels. The parameters in the two groups were 
compared. Correlation between different parameters was calculated by Pearson correlation 
analysis in both the groups. Uric acid levels (6.40 ± 1.27 vs 4.89 ± 0.21 mg/dl, P<0.001) 
were significantly higher in patients as compared to those in controls. There was 
significant increase in the levels of total cholesterol (TC), triglycerides (TAGs), LDL-C, 
VLDL-C, non-HDL cholesterol (P<0.001 in each case), in patients of dyslipidemia. 
However, significant decrease in the levels of HDL-C (P<0.001) was seen in patients 
compared to controls. LDL-C/HDL-C ratio (P<0.001), TC/HDL-C ratio (P<0.001) and 
TAG/HDL-C ratio (P<0.001) were also significantly increased in dyslipidemic subjects 
when compared to controls. Uric acid had significant correlations with TC (r=0.334, 
P<0.001), TAGs (r = 0.288, P<0.001), LDL-C (r = 0.241, P<0.001), VLDL-C (r= 0.158, 
P<0.001) and HDL-C (r= –0.652, P<0.001) in patients. Results of this study imply that 
there is higher association of hyperuricemia in dyslipidemic patients than normal subjects. 
Therefore treatment of underlying hyperuricemia should be an important aspect in 
planning the treatment strategy for dyslipidemia to reduce the cardiovascular morbidity. 
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Dyslipidemia has been long recognized as a major 
biochemical event predisposing to atherogenicity 
and cardiovascular disease (CVD). It is manifested 
by elevation or attenuation of plasma 
concentrations of lipoproteins. India is currently 
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experiencing increasing trends in mean cholesterol, 
LDL cholesterol and triglyceride levels1. In India, 
there has been an alarming increase in the 
prevalence of CVD over the past two decades so 
much so that it accounts for 24% of all deaths 
among adults aged 25–69 years2. Inflammatory 
processes have been increasingly recognized to 
play a role in pathogenesis of CVD3. Various 
circulating markers of inflammation have been 
extensively evaluated for their role as risk 
predictors4. Uric acid was once viewed as an inert 
metabolic product but recently has been shown to 
be involved in a number of cardio-metabolic 
disease states including hypertension, metabolic 
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syndrome, cardiovascular disease and diabetes5. 
Recently, the question whether it is the cause or 
effect of these inflammatory conditions has come 
into the limelight. Experimentally, uric acid (UA) 
has been shown to generate amino carbonyl 
radicals, which have pro-inflammatory, and 
antioxidant effects on vascular smooth muscle cells 
subsequently leading to cardiovascular disease6-7. 
Thus, it has now been shown to be a contributory 
causal factor in hypertension, cardiovascular 
diseases, metabolic syndrome, diabetes, non-
alcoholic fatty liver disease and chronic kidney 
disease. 
Uric acid is a weak organic acid, the final 
enzymatic end product of purine nucleotides 
degradation8. It represents a marker for high levels 
of damaging oxidative stress associated with the 
enzymes involved in uric acid production e.g. 
xanthine oxidase9. There are reports, which 
implicate uric acid as a surrogate marker for 
oxidative stress9. Though there is controversial 
opinion about pro-oxidative and antioxidant 
properties of uric acid as it is also a powerful free 
radical scavenger in humans10. 
Hyperuricemia is a metabolic consequence 
originating with different etiologies concerned with 
either increased production or decreased excretion 
of uric acid or as a combination of both. It is 
frequently associated with lifestyle related disease 
factors like gender, diet, obesity, reduced physical 
activity, increased alcohol consumption, smoking, 
increased body mass index, etc.11,12.All these 
factors are, in themselves, risk factors for Coronary 
Artery Disease (CAD) and stroke as well13. 
Therefore the definitive role of uric acid is subject 
to debate, whether it is only a co-existing marker, 
or a causative risk factor for the pathologic 
processes occurring in these diseases. 
Number of reports supported that hyperuricemia 
could be seen as an independent predictor of 
mortality in patients with coronary artery disease 
(CAD) after adjustment for classic risk factors14,15. 
However some studies did not find a similar 
relationship between serum UA and cardiovascular 
outcomes16. The relationship between serum uric 
acid and dyslipidemia is also complex and needs 
further comprehension. Although some researchers 
have shown that hyperuricemia is associated with 
dyslipidemia17, we did not come across any study 
specifically assessing the levels of uric acid in 
untreated patients of dyslipidemia. Therefore the 
present study was indented to investigate the 
independent association of serum uric acid and 
lipid profile including lipid ratios such as LDL-
C/HDL-C ratio (LDL-C/HDL-C), total 
cholesterol/HDL-C ratio (TC/HDL-C) and 
triglycerides/HDL-C ratio (TAGs/HDL-C) along 
with non-HDL-C, which can be calculated from the 






This study was conducted in the department of 
Biochemistry, Vardhman Mahavir Medical College 
and Safdarjung Hospital, New Delhi, India, for 10 
months (November 2016 to August 2017), after 
obtaining ethical clearance from the institutional 
ethical committee for human studies. This was a 
case-control study in which all dyslipidemic 
patients coming to the outpatient department of the 
hospital were recruited to the department. Controls 
comprised relatives, spouses or friends of the 
patients and staff members of the institute and were 
matched for age and sex. Written consent was 
obtained from all the participants of the study and 
their detailed medical history recorded. All 
participants were in the age group of 20-60 years 
and had no history of any cardiovascular events. 
Out of 70 patients considered for the study, 33 were 
recently diagnosed with diabetes but were 
considered in the study group, as various studies 
have shown that uric acid is a predictor of diabetes 
but diabetes does not lead to hyperuricemia18,19. 
Exclusion criteria for this study were: renal 
dysfunction, liver dysfunction, previous or present 
history of cardiovascular disease as assessed from 
history of chest pain, stroke and ECG. Those who 
had a history of diabetes for more than six months, 
alcoholics and patients on any kind of anti-
hypertensive, hypolipidemic or hypouricemic drug 
were also excluded from the study. 
 
Anthropometric and blood pressure 
measurements 
 
Weight was measured using digital scale with 
sensitivity of 0.1 kg; height was measured to the 
nearest 0.1 cm using wall-mounted scale. Body 
Mass Index (BMI) was calculated as weight in kg 
divided by squared height (m2). Waist-hip ratio 
(WHR) was calculated as ratio of waist 
circumference measured at the level of umbilicus 
after expiration to hip circumference (measured as 
maximal horizontal circumference at the level of 
the buttocks). Blood pressure was measured twice 
in the right arm of subjects who had been resting 
for at least 10 min in a seated position using a 
mercury sphygmomanometer. 
 
Blood collection and biochemical analysis 
 
Four ml of venous blood sample was collected 
aseptically from all participants, after a 12-14 hour 
overnight fast, and allowed to clot. Serum was 
separated by centrifugation at 3000 rpm for 5 min 
and was subsequently used for estimation of 
biochemical parameters, i.e. for lipid profile 
parameters (total cholesterol, HDL-C, LDL-C, 
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VLDL-C and triglycerides), serum uric acid, renal 
functions (serum urea and creatinine), liver 
functions (serum bilirubin, alanine 
aminotransferase (ALT), aspartate 
aminotransferase (AST) and alkaline phosphatase 
(ALP) and glucose levels. 
Serum cholesterol, serum triglycerides, uric acid, 
urea, creatinine and glucose were estimated using 
standard colorimetric enzymatic methods on 
Advia2400, Germany. Serum cholesterol 
estimation was carried out by using cholesterol 
esterase and cholesterol oxidase enzymes20. Serum 
triglycerides were determined after enzymatic 
hydrolysis with lipase and production of H2O2 by 
glycerol kinase and glycerol phosphate oxidase21. 
Glucose was measured using glucose oxidase 
enzyme22. H2O2 produced in all three methods 
converts 4-aminoantipyrene to red colored 
quinoneimine dye in presence of peroxidase 
enzyme. Serum urea was assayed by urease 
enzyme, creatinine by Jaffe’s kinetic method and 
uric acid by uricase method. HDL-C levels were 
analyzed by direct method according to standard 
protocol23. Direct LDL-C assay was based on the 




Results are expressed as mean ± standard deviation 
(SD). Student’s t test has been used for comparison 
between the continuous variables of the two 
groups. The relationship between uric acid level 
and other variables in lipid profile were assessed by 
Pearson’s correlation coefficients.P-value less than 
0.05 was considered to be statistically significant. 
All statistical analyses were tabulated in MS Excel 




Table 1 shows anthropometric, physiological and 
biochemical characteristics of the study population. 
A total of 140 individuals participated in this study. 
Considering the cut-off limits of WHR for 
abdominal obesity as ≥0.85 for females and ≥0.95 
for males, 89 per cent of the patients and 18 percent 
of the controls were found to be obese24. However, 
WHR in the two groups was not significantly 
different. BMI in the patients was significantly 
higher (P<0.001) than in controls. Presence of 
dyslipidemia was diagnosed when a subject had 
one or more of the following criteria (i) LDL 
cholesterol of ≥2.58 mmol/l; (ii) non- HDL 
cholesterol of ≥3.36 mmol/l; (iii) plasma 
triglycerides of ≥1.69 mmol/l; and (iv) HDL 
cholesterol of ≤1.03 mmol/l25. According to the 
cut-off values given by the Seventh Report of the 
Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High 
Blood Pressure26, 55.5 per cent of patients and 10 
per cent of controls were categorized as 
hypertensive. We noted significant difference in the 
lipid profile parameters and lipid ratios in control 
and patient group. Levels of Total cholesterol (TC), 
triglyceride (TAG), HDL-C, LDL-C, VLDL-C are 
significantly high in dyslipidemic patients 
(P<0.001 in each case) as compared to controls. 
We also observed significant increase in LDL-
C/HDL-C, TC/HDL-C and TAG/HDL-C ratios 
(P<0.001 in each case) and levels of non-HDL-C 
(P<0.001) in dyslipidemic subjects when compared 
to controls. The increase in serum uric acid levels 
in dyslipidemic patients is also statistically 
significant (P<0.001) than the control group. 
Table 1:Anthropometric, physiological and biochemical parameters of patients and controls 
 
SN Parameters Controls(n=70) Patients(n=70) P- value 
1. Age (yrs) 39.4±7.96 41.03±6.7* 0.19 
2. Male: Female ratio 33:37 38:32 - 
3. Body mass index (kg/m2) 25.68±3.32 28.79±4.59** 0.001 
4. SBP (mmHg) 121.2 ± 6.17 140.8 ± 8.47** 0.001 
5. DBP (mmHg) 73.96 ± 9.6 91.9 ± 11.1** 0.001 
6. Waist Hip ratio 0.90±0.08 0.92±0.09* 0.16 
7. Total Cholesterol(mg/dl) 150.07± 5.02 240.56±11.31** 0.001 
8. TAGs(mg/dl) 99.02± 12.72 233.95± 53.74** 0.001 
9. HDL(mg/dl) 42.79± 2.45 37.10± 4.21** 0.001 
10. LDL(mg/dl) 94.82± 0.93 135.40± 0.65** 0.001 
11. VLDL(mg/dl) 18.26± 4.39 68.05±24.86** 0.001 
12. LDL/HDL 2.66± 0.18 3.87± 1.85** 0.001 
13. Total Cholesterol/HDL 4.18± 0.06 6.19± 2.13** 0.001 
14. Triglycerides/HDL 2.73± 0.23 7.068± 4.0** 0.001 
15. Non-HDL(mg/dl) 113.08± 3.46 203.46 ± 25.52** 0.001 
16. Uric acid(mg/dl) 4.89± 0.21 6.40± 1.27** 0.001 
TAGs, triglycerides; HDL, high-density lipoprotein; LDL, low density lipoprotein; VLDL, very low density 
lipoprotein. P*>0.05: Non- significant. P**<0.05: Significant. 
Suneja et al / Correlation between hyperuricemia and lipid profile 
	
	
Copyrighted © by Dr. Arun Kumar Agnihotri. All rights reserved | DOI: http://dx.doi.org/10.4314/ijmu.v13i1.2  
 
6 
Table 2 shows that there is no significant 
difference in the levels of urea and creatinine (P> 
0.05 each) in patients and controls, which depicts 
normal kidney functions in the two groups. Liver 
function tests, namely total bilirubin, direct 
bilirubin. Indirect bilirubin, alanine 
aminotransferace and alkaline phosphatase (P 
>0.05 in each case) did not show significant 
difference in the two groups and signify normal 
liver functions. However levels of blood glucose 
are statistically different (P<0.05), as we have 
considered newly diagnosed diabetics (<6 months) 
in our study. 
Figure 1 depicts positive correlations between uric 
acid and the lipid profile parameters viz TC 
(r=0.334, P<0.001), TAGs (r=0.288, P<0.001), 
LDL-C (r=0.241, P<0.001) and VLDL-C (r=0.158, 
P<0.001). However, negative correlation was found 
between uric acid and HDL-C (r= -0.652, 
P<0.001). 
 
Table 2:Fasting blood glucose, hepatic and renal markers in patients and controls 
 
SN Particulars Controls(n=70) Patients(n=70) P- value 
1 Glucose(mg/dl) 94.08± 22.63 119.85± 5.65** 0.0001 
2 Total Bilirubin(mg/dl) 0.65±0.27 0.63± 0.20* 0.5361 
3 Direct Bilirubin(mg/dl) 0.21±0.07 0.20±0.06* 0.3657 
4 Indirect Bilirubin(mg/dl) 0.44±0.2 0.46±0.1* 0.421 
5 AST 24.75±0.70 25.97±2.48** 0.0001 
6 ALT 25.32±7.78 27.69± 8.90* 0.0957 
7 ALP 91.08±19.79 90.97±14.84* 0.9704 
8 Urea(mg/dl) 22.46± 1.20 22.43± 1.13* 0.8792  
9 Creatinine (mg/dl) 0.64 ± 0.17 0.67± 0.08* 0.1838 
AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase. P*>0.05: Non- 
significant. P**<0.05: Significant. 
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Our study illustrated a strong association between 
serum uric acid levels and lipid profile of 
dyslipidemic patients after controlling for sex, age 
and BMI. Several epidemiological studies highlight 
the contribution of dyslipidemia to cardiovascular 
risk27,28. Moreover, serum uric acid has been 
observed to be highly associated with the 
development of cardiovascular disease for more 
than 50 years. Cardiovascular diseases (CVDs) are 
consequences of atherosclerosis and are related to 
oxidative stress29. Uric acid represents a marker for 
high levels of damaging oxidative stress associated 
with increased xanthine oxidase activity30. It is a 
product of purine nucleotide catabolism, the 
process catabolized by hepatic enzyme xanthine 
oxidoreductase (XOR), which enables the oxidation 
of hypoxanthine to xanthine and its further 
oxidation to uric acid31. It not only catalyzes the 
production of uric acid but also nitric oxide and 
reactive oxygen species, which potentially damage 
nucleic acids and proteins and convert 
polyunsaturated fatty acids to lipids32. Thus in this 
process of catabolism, reactive oxygen species 
(ROS) are generated as by-products, having 
significant role in the increased oxidative stress31. 
Experimental data also suggests the impact of uric 
acid on oxidative stress per se, via mechanism that 
NO- labeled 1,3-15N2 uric acid (15N2-UA) under 
anaerobic conditions in several different media, 
including human plasma and endothelial cell 
lysates results with the production of 5-aminouracil 
(5-AU) and 6-aminouracil (6-AU)33. 
Although in experimental studies it has been shown 
that rats administered with uric acid exhibited 
dyslipidemia and glucose intolerance, which were 
probably mediated by hypothalamic inflammation 
and hypothalamic neuroendocrine alterations as 
uric acid produces this inflammatory response 
through activation of NF-кB in the hypothalamus34, 
very few studies in humans link the association of 
uric acid with dyslipidemia35. 
Several past studies have shown that high levels of 
plasma TAG are related to hyperuricemia36,37 and 
potential mechanism for the same could be 
explained on the basis that TAG synthesis 
accelerates the de novo synthesis of ribose-5-
phosphate to phosphoribosyl pyrophosphate(PRPP) 
through the common metabolic pathway of NADP-
NADPH, and as a result, uric acid production 
increases38.A positive correlation of uric acid and 
TAG as depicted in our study is in line with these 
studies. Negative correlation observed between uric 
acid and HDL-C is also in support from some 
previous studies39,40. 
Detection of dyslipidemia at a preliminary level 
and its proper management will be able to prevent 
the morbidity and complications of CVD. Positive 
correlation between hyperuricemia and 
dyslipidemia, as illustrated in our study, may 
facilitate the claim that serum uric acid could serve 
as a simple and economically viable biomarker in 
CAD patients. Moreover, due to strong concurrence 
of dyslipidemia and hyperuricemia, it is advisable 
to develop appropriate treatment guidelines, taking 
into consideration the pharmacologic measures at 
improving hyperuricemia and holistic approach for 
treating CVD risk factors including diet and life 
style modification. 
Traditionally, cholesterol measurements were 
considered most accurate at predicting the risk of 
atherosclerosis, especially in those at lower or 
higher ends of the risk spectrum, but these 
measurements are less helpful in the majority of 
people whose risk falls somewhere in between the 
spectrum. Therefore, recently lipid ratios have 
gained much attention. Changes in these ratios 
represent a better indicator for risk reduction in 
CAD patients than the absolute values of individual 
lipoproteins41. 
In the Helsinki Study, a five-year clinical trial of 
more than 4,000 middle-aged men with elevated 
lipids, the LDL-C/HDL-C ratio and TC/HDL-C 
ratio had more prognostic value28.Moreover, the 
LDL-C/HDL-C and TC/HDL-C ratios help in 
initiating lipid-lowering therapy42. Results of 
prospective studies43 have suggested that a high 
LDL-C/HDL-C ratio combined with 
hypertriglyceridemia, together referred to as 
atherogenic dyslipidemis44, along with TC/HDL-C 
ratio may be simpler cumulative markers for 
Ischemic Heart Disease (IHD). Also current NCEP 
guidelines recommend non-HDL-C as a secondary 
target of therapy if triglyceride levels exceed 
200mg/dl45. 
Thus in our study, we have taken into consideration 
the lipid fractions i.e. LDL-C/HDL-C, TC/HDL-C 
and TAG/HDL along with non-HDL-C as more 
accurate markers of dyslipidemia and observed 
significant increase in their values in patients when 
compared to controls (Table 1). Our results are in 
accordance to the study conducted by Sathiya et 
al46, who also found altered values of these 
parameters in CAD patients 
The limitations of this study warrant consideration. 
Firstly, the population size was small and only 
included patients from southern region of the 
National Capital Territory of Delhi, as well as the 
adjoining areas of the neighboring state. Thus, our 
population was not representative of the entire 
Indian population. Secondly, we did not analyze 
our patients gender-wise because of small sample 
size. It is also possible that unmeasured 
confounding variables may exist.  The strength of 
the study was that treatment-naïve dyslipidemic 
subjects were considered for the study. Also, we 
studied lipid fractions in addition to the standard 
parameters of lipid profile in patients and controls. 
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Our study showed significant higher levels of uric 
acid in dyslipidemic subjects. Since dyslipidemia 
predicts the risk of CAD, it is important to consider 
uric acid levels in these patients for more 
comprehensive strategic management of risk 
factors. Visa-versa, while establishing the diagnosis 
of hyperuricemia, clinical suspicion of coexistent 
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